Brief: DongKook Pharmaceutical to divest contrast medium business into new subsidiary
21/03/2017 06:29
March 21 (Reuters) - DongKook Pharmaceutical Co Ltd
086450.KQ :
* Says it will divest contrast medium business into new
subsidiary named Dongkook Life Science Co., Ltd
* Expected divestiture effective date is May 1
Source text in Korean: https://goo.gl/jSsahh
Further company coverage: 086450.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on DongKook Pharmaceutical
See all newsBrief: Faes Farma Signs Exclusive License And Supply Agreement For Uresco In 13 Latin American Countries
Brief: Dongkook Pharmaceutical To Divest 7 Billion Won Worth Of Own Shares
Brief: Dongkook Pharmaceutical Q2 Operating Profit 22 Billion Won, Up 15% From Year Earlier
Brief: Dongkook Pharmaceutical To Acquire Shares Worth 30.7 Billion Won In Rebom Cosmetics
Uranium Energy up after $175 mln deal for Rio Tinto's Wyoming uranium assets